GleamWall
中文EN

CLRB Cellectar Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1279704 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-37.2%
TTM EPS YoY70.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-170.0%
ROA-116.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets24.6%
Debt / equity0.00x
Current ratio4.44x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$5.44M$4.56M$3.01M$3.16M$2.52M$2.39M$3.43M$6.21M
SG&A expense$2.67M$2.64M$2.79M$2.53M$2.33M$3.65M$2.97M$6.54M
Operating income-$8.10M-$7.20M-$5.79M-$5.69M-$4.85M-$6.04M-$6.40M-$12.74M
Net income-$7.97M-$6.93M-$5.65M-$5.30M-$4.44M-$5.45M-$6.60M-$2.36M
EBITDA———-$5.64M-$4.80M-$5.98M-$6.34M-$12.68M
EPS (basic)-0.46-0.57-1.33—-1.41-3.39-4.30—
EPS (diluted)-0.46-0.57-1.33—-1.41-3.39-4.30—
Weighted avg. shares (diluted)17.46M12.23M4.24M—3.16M1.61M1.54M—
Balance sheet
Cash & equivalents$24.58M$33.99M$8.35M$13.20M$12.55M$11.04M$13.91M$23.29M
Current assets$25.71M$34.88M$9.27M$14.04M$13.62M$12.62M$14.89M$24.25M
PP&E, net$268,905$304,173$339,697$549,405$595,271$647,549$700,826$757,121
Total assets$29.74M$36.64M$11.12M$14.98M$14.63M$13.70M$16.04M$25.47M
Current liabilities$5.80M$5.24M$4.87M$4.75M$4.91M$5.87M$6.02M$9.39M
Total liabilities$7.33M$6.77M$6.40M$5.06M$5.25M$6.23M$6.41M$9.80M
Shareholders' equity$22.42M$29.87M$3.34M$8.54M$8.00M$6.09M$8.25M$14.29M
Shares outstanding10.04M8.25M4.24M4.24M3.19M1.81M46.08M1.54M
Cash flow statement
Operating cash flow-$9.41M-$6.01M-$4.85M-$4.34M-$4.28M-$5.12M-$9.38M-$10.91M
Capital expenditure$0$0$3,378————$61,286
Free cash flow-$9.41M-$6.01M-$4.85M————-$10.97M
Investing cash flow$0$0-$3,378————-$61,286
Financing cash flow$5——$4.99M$5.79M——$0
Depreciation & amortization———$49,461$52,277$55,564$56,295$68,571
Stock-based compensation$518,273$428,306$451,869$567,788$567,788$565,391$562,737$1.49M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.